Delivery Order SPE2DB24D3013-SPE2DB25FFPGQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $31,503.39 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed price contract is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $14,097.56 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic immunosuppressant medication used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4,569,036,577 units of DUPIXENT 300 MG/2 ML pens (2 ML vials) valued at $5,656.54 with a firm fixed price structure. The award was made on August 8, 2025, with an ultimate completion date of August 11, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its Corporate Office location, consistent...
- The Defense Logistics Agency awarded a delivery order valued at $12,879.52 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen auto-injectors on August 8, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $26,836.77 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion targeted for July 25, 2025. This firm fixed-price contract represents a single delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was not set-aside and resulted from competitive procurement,...
- The Defense Logistics Agency awarded a $22,738.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML). The contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025, and is being fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injectors, valued at $6,777.99, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPGQDelivery Order
The Defense Logistics Agency awarded a $14,397.15 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen auto-injectors. The contract, finalized on August 12, 2025, with completion targeted for August 13, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open solicitation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling supply of medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems worldwide. DUPIXENT (dupilumab), a specialty biologic medication used primarily for atopic dermatitis, asthma, and eosinophilic conditions, represents the type of critical pharmaceutical inventory maintained under this prime vendor agreement to support Defense Health Agency and broader federal healthcare procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.4k | 8/12/25 |